CAMBRIDGE, England, AHMEDABAD, India and NORTH BRUNSWICK, New
Jersey, June 23, 2011 /PRNewswire/ —
Oxygen Healthcare Ltd. (O2h), a Piramal Group
Company and Chromocell Corporation, an
emerging life sciences company active in both flavors and
therapeutics discovery, today signed an agreement under which O2h
will provide supplemental chemistry support to further accelerate
the drug discovery initiatives at Chromocell.
“I have known O2h for a number of years and am impressed by its
delivery focus,” said David Palling, Senior Vice President,
Therapeutics, Chromocell. “With the in-house chemistry resources
and the faster-than-expected progress made in our therapeutic
programs, complementary support from O2h will help us maximize
resources and reach our end-points quicker. I look forward to
this opportunity of working with them to advance our drug discovery
pipeline.”
O2h will provide Chromocell during 2011 with focused libraries
of compounds at mg-g scale for various projects.
Sunil Shah, CEO, O2h said “O2h has optimized its operations for
discovery speed and delivery to help accelerate drug discovery
efforts of companies in the United States, Europe and Japan. It is
our privilege to work with the experienced team led by Dr. Palling
at Chromocell,”
About Chromocell Corporation
Chromocell, founded in 2002 and headquartered in North Brunswick, N.J., is an emerging
life sciences company which improves consumer products and patient
lives through breakthrough science and technologies. It is
focused on the discovery and development of both flavors and
therapeutics through its pioneering Chromovert ® technology, a
process that enables the company to use naturally occurring systems
that mimic human biology as part of its discovery platform.
Chromocell works with worldwide consumer goods companies to
develop fla
‘/>”/>
